DelveInsight’s “Liver Cirrhosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Liver Cirrhosis, historical and forecasted epidemiology as well as the Liver Cirrhosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Discover Key Insights into the Liver Cirrhosis Market with DelveInsight’s In-Depth Report @ Liver Cirrhosis Market Size

 

Key Takeaways from the Liver Cirrhosis Market Report

• The total diagnosed prevalent cases of Liver Cirrhosis in the US comprised approximately 2,070 thousand in 2023 and are projected to increase during the forecast period.
• As per DelveInsight’s estimates, the US alone accounts the highest number of total diagnosed prevalent cases, of liver cirrhosis in the 7MM, followed by EU4 and the UK and Japan, contributing to 24% and 14% of all liver cirrhosis cases respectively.
• The etiology-specific distribution of diagnosed prevalent cases of liver cirrhosis showed MASH, HCV, HVB, ALD, and PBC comprised 13%, 45%, 15%, 26%, and 2% cases in Japan, respectively.
• EU4 and the UK accounted for around 830 thousand diagnosed prevalent cases of liver cirrhosis in 2023. Of these cases, Germany accounted for the highest number of cases.
• The leading Liver Cirrhosis Companies such as Madrigal Pharmaceuticals Inc., Galectin Therapeutics, Akero Therapeutics, Lipocine Inc, Conatus Pharma, Norgine, Madrigal Pharma, Gwo Xi Stem Cell Applied Tech, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland Pharma, Lipocine Inc., Intercept Pharma, Sanofi, HK inno.N Corporation, Pfizer, and others
• Promising Liver Cirrhosis Therapies such as Resmetirom, Belapectin, Efruxifermin, LPCN 1148, IDN-6556, NRL972, Resmetirom, GXHPC1, GI262570, Rifaximin, BMS-986263, MNK6106, conivaptan, LPCN 1148, INT-747, Satavaptan, oltipraz, Obeticholic Acid (OCA), IDN-6556, Pregabalin, and others

 

Navigate the complexities of the Liver Cirrhosis Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Liver Cirrhosis Market Forecast. Click here to get more insights @ Liver Cirrhosis Treatment Market

 

Liver Cirrhosis Epidemiology Segmentation in the 7MM

• Total Prevalence of Liver Cirrhosis
• Prevalent Cases of Liver Cirrhosis by severity
• Gender-specific Prevalence of Liver Cirrhosis
• Diagnosed Cases of Episodic and Chronic Liver Cirrhosis

 

Download the report to understand which factors are driving Liver Cirrhosis epidemiology trends @ Liver Cirrhosis Prevalence

 

Liver Cirrhosis Emerging Drugs Profile

 

• Efruxifermin (AKR-001): Akero Therapeutics, Inc.

Efruxifermin (EFX), formerly AKR-001, is Akero’s lead product candidate for MASH cirrhosis. EFX is designed to offer convenient once-weekly SC dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine if approved. EFX is currently being evaluated in Phase IIb clinical trials in patients with biopsy-confirmed NASH: the SYMMETRY study in cirrhotic patients with compensated F4 fibrosis. EFX shows the potential to be an effective treatment for patients with cirrhosis due to MASH. Currently the drug is in Phase II of clinical development for the treatment of MASH cirrhosis.

 

• Belapectin (GR-MD-02): Galectin Therapeutics Inc.

Belapectin (GR-MD-02), a galectin-3 inhibitor, has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension and prevent its complication: the development of esophageal varices. Belapectin can potentially treat many diseases due to galectin-3’s involvement in multiple key biological pathways such as fibrosis, immune cell function and immunity, cell differentiation, cell growth, and apoptosis (cell death). The importance of galectin-3 in the fibrotic process is supported by experimental evidence. Animals with the galectin-3 gene “knocked-out” can no longer develop fibrosis in response to experimental stimuli compared to animals with an intact galectin-3 gene. The company is using galectin-3 inhibitors to treat advanced liver fibrosis and liver cirrhosis in MASH patients. They have completed two Phase I clinical studies, a Phase II clinical study in MASH patients with advanced fibrosis (NASH-FX) and a second Phase IIb clinical trial in MASH patients with compensated cirrhosis and portal hypertension (NASH-CX).

 

• Zibotentan/dapagliflozin: Astrazeneca

AstraZeneca’s combination therapy, zibotentan/dapagliflozin, is currently in Phase II clinical development targeting liver cirrhosis. This innovative treatment leverages the synergistic mechanisms of zibotentan, an endothelin A receptor antagonist, and dapagliflozin, a SGLT2 inhibitor marketed as Farxiga in the US and Forxiga globally. The small molecule duo is being evaluated in the ZEAL-UNLOCK study (Phase IIb) to assess its safety profile. Initiated in February 2024, this trial aims for a primary completion by January 2025. The study’s impactful results could redefine therapeutic strategies for liver cirrhosis, addressing a significant unmet medical need.

 

Liver Cirrhosis Market Outlook

With first approved therapy for advanced hepatic cirrhosis in 2024, the market outlook for liver cirrhosis is expected to expand. The most popular drug classes used to treat Liver Cirrhosis include antivirals, antibiotics, antifibrotics, etc. For individuals with severely decompensated cirrhosis, early antiviral therapy is crucial. Antiviral therapy for Chronic Hepatitis B’s primary objective is to reduce hepatic dysfunction and save patients from death. Interferon alpha (IFN) and nucleos (t) ide analogs are antiviral medications that are clinically used. The launch of emerging therapies, such as Belapectin/ GR-MD-02 (Galectin Therapeutics Inc.), Efruxifermin (Akero Therapeutics, Inc), Zibotentan/dapagliflozin (Astrazeneca), and others are expected to impact the market positively. The approval of these therapies could significantly impact market dynamics, although their success rates remain uncertain.

 

Get In-Depth Knowledge on Liver Cirrhosis Market Trends and Forecasts with DelveInsight @ Liver Cirrhosis Treatment Market

 

Liver Cirrhosis Therapies and Companies

• Resmetirom: Madrigal Pharmaceuticals Inc.
• Belapectin: Galectin Therapeutics
• Efruxifermin: AkeroTherapeutics
• LPCN 1148: Lipocine Inc
• IDN-6556: Conatus Pharma
• NRL972: Norgine
• Resmetirom: Madrigal Pharma
• GXHPC1: Gwo Xi Stem Cell Applied Tech
• GI262570: GlaxoSmithKline
• Rifaximin: Bausch Health
• BMS-986263: Bristol-Myers Squibb
• MNK6106: Mallinckrodt
• conivaptan: Cumberland Pharma
• LPCN 1148: Lipocine Inc.
• INT-747: Intercept Pharma
• Satavaptan: Sanofi
• oltipraz: HK inno.N Corporation
• Obeticholic Acid (OCA): Intercept Pharma
• IDN-6556: Conatus Pharmaceuticals Inc.
• Pregabalin: Pfizer

 

Scope of the Liver Cirrhosis Market Report

• Study Period: 2020–2034
• Coverage: 7MM
• Liver Cirrhosis Companies: Madrigal Pharmaceuticals Inc., Galectin Therapeutics, Akero Therapeutics, Lipocine Inc, Conatus Pharma, Norgine, Madrigal Pharma, Gwo Xi Stem Cell Applied Tech, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland Pharma, Lipocine Inc., Intercept Pharma, Sanofi, HK inno.N Corporation, Pfizer, and others
• Liver Cirrhosis Therapies: Resmetirom, Belapectin, Efruxifermin, LPCN 1148, IDN-6556, NRL972, Resmetirom, GXHPC1, GI262570, Rifaximin, BMS-986263, MNK6106, conivaptan, LPCN 1148, INT-747, Satavaptan, oltipraz, Obeticholic Acid (OCA), IDN-6556, Pregabalin, and others
• Liver Cirrhosis Therapeutic Assessment: Liver Cirrhosis current marketed and Liver Cirrhosis emerging therapies
• Liver Cirrhosis Market Dynamics: Liver Cirrhosis market drivers and Liver Cirrhosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Liver Cirrhosis Unmet Needs, KOL’s views, Analyst’s views, Liver Cirrhosis Market Access and Reimbursement

 

Gain a strategic edge in the Liver Cirrhosis Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Liver Cirrhosis Market Forecast. Click here to lead in advancements @ Liver Cirrhosis Clinical Trials Assessment

 

Table of Contents

1. Liver Cirrhosis Market Report Introduction

2. Executive Summary for Liver Cirrhosis

3. SWOT analysis of Liver Cirrhosis

4. Liver Cirrhosis Patient Share (%) Overview at a Glance

5. Liver Cirrhosis Market Overview at a Glance

6. Liver Cirrhosis Disease Background and Overview

7. Liver Cirrhosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Liver Cirrhosis

9. Liver Cirrhosis Current Treatment and Medical Practices

10. Liver Cirrhosis Unmet Needs

11. Liver Cirrhosis Emerging Therapies

12. Liver Cirrhosis Market Outlook

13. Country-Wise Liver Cirrhosis Market Analysis (2020–2034)

14. Liver Cirrhosis Market Access and Reimbursement of Therapies

15. Liver Cirrhosis Market Drivers

16. Liver Cirrhosis Market Barriers

17. Liver Cirrhosis Appendix

18. Liver Cirrhosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage